Aurora Cannabis Faces Class Action Over Cannabinoid Hyperemesis Syndrome Risk

Aurora Cannabis is facing a class action led by a Canadian military veteran, who alleges that the company didn’t adequately warn consumers about Cannabis Hyperemesis Syndrome (CHS), a condition the plaintiff says was caused by its products.

The class action was certified last month in Ontario’s Superior Court of Justice and is being brought by Canadian law firm Sotos Class Actions. It seeks to represent all individuals in Canada who purchased Aurora Cannabis products between February 2015 and May 2025 and were later diagnosed with CHS.

Aurora Cannabis, based in Canada, is one of the largest medical cannabis companies in the industry and operates globally, with a presence in North America, Europe, Latin America, and Australia. It als trades on the Toronto Stock Exchange and Nasdaq. In January, the company announced the release of its first medical cannabis product grown in Germany, following the legalization of recreational cannabis for personal use that eased restrictions in the country’s medical cannabis market.

The plaintiff, identified as V.T., alleges she developed CHS after using Aurora’s cannabis products, which were prescribed to treat post-traumatic stress disorder.